Literature DB >> 25466585

Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment.

Angela Vasaturo1, Martijn Verdoes1, Jolanda de Vries1, Ruurd Torensma1, Carl G Figdor2.   

Abstract

Cancer cells evolve from normal cells throughout life and are usually recognized by our immune system and destroyed, a process called immunosurveillance. Unfortunately, in some instances cancer cells paralyze our immune system, resulting in outgrowth and spreading of the tumor. Understanding the complexity of immunomodulation by tumors is important for the development of therapeutical strategies. Nowadays, various approaches have been developed to enhance anti-tumor immune responses and abrogate the immune dampening effect of the tumor and its surrounding environment, including dendritic cell-based vaccines, therapies to counteract myeloid derived suppressor cell function within the tumor and antagonists of inhibitory signaling pathways to overcome 'immune checkpoints'. The challenge is now to find the right combination of immune based therapies to fully restore immune function and provide a more efficacious and enduring anti-tumor response.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Cancer; Dendritic cell vaccination; Immunosuppression; Immunotherapy; Tumor immunology; Tumor microenvironment

Mesh:

Substances:

Year:  2014        PMID: 25466585     DOI: 10.1016/j.imbio.2014.11.007

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  6 in total

1.  Enzyme-instructed and mitochondria-targeting peptide self-assembly to efficiently induce immunogenic cell death.

Authors:  Debin Zheng; Jingfei Liu; Limin Xie; Yuhan Wang; Yinghao Ding; Rong Peng; Min Cui; Ling Wang; Yongjie Zhang; Chunqiu Zhang; Zhimou Yang
Journal:  Acta Pharm Sin B       Date:  2021-07-14       Impact factor: 14.903

2.  Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents.

Authors:  Nataša Obermajer; Julie Urban; Eva Wieckowski; Ravikumar Muthuswamy; Roshni Ravindranathan; David L Bartlett; Pawel Kalinski
Journal:  Nat Protoc       Date:  2018-01-18       Impact factor: 13.491

3.  Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.

Authors:  Diana Llopiz; Marta Ruiz; Leyre Silva; David Repáraz; Belén Aparicio; Josune Egea; Juan J Lasarte; Esther Redin; Alfonso Calvo; Matthew Angel; Jay A Berzofsky; David Stroncek; Pablo Sarobe
Journal:  Cancer Lett       Date:  2020-11-21       Impact factor: 8.679

Review 4.  Immunogenic cell death in cancer therapy: Present and emerging inducers.

Authors:  Jingyi Zhou; Gangyang Wang; Yinze Chen; Hongxia Wang; Yingqi Hua; Zhengdong Cai
Journal:  J Cell Mol Med       Date:  2019-06-18       Impact factor: 5.310

5.  Altered Hepa1-6 cells by dimethyl sulfoxide (DMSO)-treatment induce anti-tumor immunity in vivo.

Authors:  Zhengyu Jiang; Hongxia Zhang; Ye Wang; Bin Yu; Chen Wang; Changcheng Liu; Juan Lu; Fei Chen; Minjun Wang; Xinlu Yu; Jiahao Lin; Xinghua Pan; Pin Wang; Haiying Zhu
Journal:  Oncotarget       Date:  2016-02-23

6.  Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy.

Authors:  Imerio Capone; Paolo Marchetti; Paolo Antonio Ascierto; Walter Malorni; Lucia Gabriele
Journal:  Front Immunol       Date:  2018-03-21       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.